Korean J Urol.  1997 Sep;38(9):945-950.

A Comparison of Mitomycin C, Pasteur Strain BCG and Tice Strain BCG for the Prophylaxis of Superficial Bladder Tumor

• Lee JH
• Lee YG

Abstract

PURPOSE: We compared the efficacies of intravesical instillation of the mitomycin (MMC), Pasteur bacillus Carmette-Guerin (B.C.G.)(PBCG) and Tice B.C.G (TBCG) in patients with high risk superficial transitional cell carcinoma of bladder.
MATERIALS AND METHODS
Our study included 49 patients with the stage T1 and the stage Ta with recurrent, grade 3, multiple or greater than 3 cm sized tumor. After complete transurethral resection of all visible tumors, 11 out of them were treated intravesically with 40 mg mitomycin C once a week for 8 consecutive weeks, 21 with 8~15 x 10(6) colony-forming units (CFU) Pasteur BCG and 17 with 2~8 x 10(8) CFU Tice BCG once a week for 6 consecutive weeks.
RESULTS
The mean followup periods were 51.6 months for MMC group, 33 months for PBCG group and 17.8 months for TBCG group. The overall recurrence rates were 72.7% for MMC group, 38% for PBCG group and 17.6% for TBCG group (p=0.014). The mean times for recurrence were 8.1 months for MMC group, 9.7 months for PBCG group and 13.3 months for TBCG group (p=0.610). The tumor progression rates in each group were following, 3/11 (27%) for the MMC group, 2/21 (9.5%) for the PBCG group and 1/17 (5.9%) for the TBCG group (p>0.05). The difference in recurrence free survival rates between MMC group and PBCG group and between TBCG group and PBCG group was not significant (p>0.05). The difference in recurrence free survival rates between MMC group and TBCG group was significant (p=0.0012).
CONCLUSIONS
Our result showed that TBCG group was superior to the others in recurrence rate and recurrence free survival rate, but further study including longterm followup and various HCG instillation dosage Is needed In order to confirm the preventive efficacy of BCG according to strain in superficial bladder tumor.

MeSH Terms

Administration, Intravesical
Bacillus
Carcinoma, Transitional Cell
Follow-Up Studies
Humans
Mitomycin*
Mycobacterium bovis*
Recurrence
Stem Cells
Survival Rate
Urinary Bladder Neoplasms*
Urinary Bladder*
Mitomycin